Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on: October 12,2023 261

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on:October 12,2023 261

Machine-learning tool to match treatment for cancer patients

byTechnion - Israel Institute of TechnologySummary of pipeline predictions. a An overview of the RNA-MuTect-WMN pipeline: In the training set (n = 100, green arrows), RNA-MuTect is applied on tu

Updated on: December 22,2023 14

Machine-learning tool to match treatment for cancer patients

byTechnion - Israel Institute of TechnologySummary of pipeline predictions. a An overview of the RNA-MuTect-WMN pipeline: In the training set (n = 100, green arrows), RNA-MuTect is applied on tu

Updated on:December 22,2023 14

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on: October 11,2023 66

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on:October 11,2023 66

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on: October 15,2023 142

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on:October 15,2023 142

What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on: October 30,2023 26

What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on:October 30,2023 26

Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local re

Updated on: December 19,2023 10

Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local re

Updated on:December 19,2023 10

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on: October 12,2023 6

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on:October 12,2023 6

Vemurafenib Induces Deep, Durable Remissions in Heavily Pretreated Hairy Cell Leukemia

October 25, 2019Kristi RosaAgnieszka Janus, MD, PhD, shares perspective on three cases of patients with HCL who were given vemurafenib after having progressed on multiple lines of treatment.Agnieszka

Updated on: October 24,2023 2

Vemurafenib Induces Deep, Durable Remissions in Heavily Pretreated Hairy Cell Leukemia

October 25, 2019Kristi RosaAgnieszka Janus, MD, PhD, shares perspective on three cases of patients with HCL who were given vemurafenib after having progressed on multiple lines of treatment.Agnieszka

Updated on:October 24,2023 2

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

Updated on: December 19,2023 32

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

Updated on:December 19,2023 32

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on: October 30,2023 6

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on:October 30,2023 6

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023 76

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023 76

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on: December 19,2023 15

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on:December 19,2023 15